The market and the possibilities of biopharmaceuticals industry in Brazil

Authors

  • Renata Leite Tanaka PUC-SP
  • Maria Cristina Sanches Amorim PUC-SP

Keywords:

Key-words, drug industry, pharmaceutical preparations, biosimilar pharmaceuticals, biopharmaceutics, biotechnology.

Abstract

ABSTRACT
In the last decade, the production of biopharmaceuticals is a major pharmaceutical company's strategy around the world. The challenge for the Brazilian State and national pharmaceutical organizations participate in this booming segment and with important effects on public policies for medicines. The information on the thread are dispersed, so the article's objectives are to describe the market in Brazil and point the main debates on the insertion of the domestic industry in the production of products of biotechnology base. The article methodology consisted in compiling the information scattered in various places of public and private institutions and organization of subjects considered relevant to understanding of the market and its controversies. The study showed that the legal, scientific and regulatory controversies surrounding the national production of biopharmaceuticals is based on the contention for a big potential market formed by the Government procurement and organization strategies.

Downloads

Download data is not yet available.

Author Biographies

Renata Leite Tanaka, PUC-SP

Economista, mestranda no programa de estudos pós-graduados em administração da PUC-SP

Maria Cristina Sanches Amorim, PUC-SP

Economista, professora titular do departamento de economia e do programa de pós-graduação em administração da PUC-SP.

References

Gadelha CA, coordenador. Perspectivas do investimento em saúde. Rio de Janeiro: UFRJ; 2008/2009.

Brasil. Ministério da Saúde. Complexo Industrial: Brasil amplia a produção de medicamentos biológicos [Internet]. Brasília: Ministério da Saúde; 2013 [acesso em 06 maio 2014]. Disponível em: http://www.blog.saude.gov.br/complexo-industrial-brasil-amplia-producao-de-medicamentos-biologicos-/.

Brandão CM, Guerra Júnior AA, Cherchiglia ML, Andrade EI, Almeida AA, Silva GD, et al. Gastos do Ministério da Saúde do Brasil com medicamentos de alto custo: uma análise centrada no paciente. Value Health. 2011;14(5):S71-7.

Medicamentos biológicos para o tratamento de artrite reumatoide. BRATS Bol Bras Aval Tecnol Saúde. 2012;6(19):1-13.

IMS Health. Shaping the biosimilars opportunity: a global perspective on the envolving biosimilars landscape. London: IMS Health; 2011.

Evaluate Pharma. World preview 2016. Estados Unidos, 2010.

Campbell D. Pharmerging markets. Apresentação realizada no seminário Partnering for Global Health Forum, Biotechnology, Washington, DC, 2011.

Storpirtis S. Biossimilares: aspectos científicos e regulatórios. São Paulo: USP; 2014.

Brasil. Ministério da Saúde. Visão geral do Complexo Industrial da Saúde e o papel dos laboratórios públicos. São Paulo: FURB; 2011.

Zhang JJ. Chinese biopharmaceutical industry: current state and future development. China: Consultoria JZMed; 2010.

Zhenzhen L, Jiuchun Z, Ke W, Thorsteinsdóttir H, Quach U, Singer PA, Daar AS. Health biotechnology in China: reawakening of a giant. Nat Biotechnol. 2004;22:13-8.

Reis C, Pieroni JP, Souza JOB. Biotecnologia para saúde no Brasil. BNDES Setorial. 2010;32:193-230.

Brasil. Ministério da Saúde. Portaria nº 1.284, de 26 de maio de 2010 [Internet]. Disponível em: http://bvsms.saude.gov.br/bvs/saudelegis/gm/2010/prt1284_26_05_2010.html.

Published

2014-06-26

How to Cite

1.
Tanaka RL, Amorim MCS. The market and the possibilities of biopharmaceuticals industry in Brazil. Rev. Fac. Ciênc. Méd. Sorocaba [Internet]. 2014Jun.26 [cited 2024Dec.30];16(2):86-92. Available from: https://revistas.pucsp.br/index.php/RFCMS/article/view/19691

Issue

Section

Original Article